Q3 revenues grew 8.4% YoY to | 8837 crore (I-direct estimate: | 8636 crore). US formulations grew 10.8% YoY to | 2761 crore. Indian formulations grew 9.4% YoY to | 2753 crore. Emerging markets business grew 8.4% YoY to | 1507 crore. RoW markets business grew 15.6% YoY to | 1276 crore. API segment de-grew 9.4% YoY to | 485 crore. EBITDA margins expanded 465 bps YoY to 27.2% (I-direct estimate: 23.0%) due to lower other expenditure and better gross margins. Delta vis--vis I-direct estimates was mainly due to significantly lower other expenditure. EBITDA grew 30.7% YoY to | 2406...